Oxford Biomedica PLC Oxford Biomedica Signs Agreement with Arcellx (3584V)
December 13 2021 - 2:00AM
UK Regulatory
TIDMOXB
RNS Number : 3584V
Oxford Biomedica PLC
13 December 2021
Oxford Biomedica Signs Licence & Supply Agreement with
Arcellx, Inc. for LentiVector(R) Platform for CAR-T
Therapeutics
Oxford, UK - 13 December 2021: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Group"), a leading gene and cell
therapy group, today announces that it has signed a new Licence and
Supply Agreement ("LSA") with Arcellx, Inc. ("Arcellx"), a
Gaithersburg MD.-based biotechnology company developing novel,
adaptive and controllable cell therapies for the treatment of
patients with cancer and autoimmune diseases. The LSA grants
Arcellx a non-exclusive licence to Oxford Biomedica's
LentiVector(R) platform for its application in select Arcellx CAR-T
programmes and puts in place a three-year Clinical Supply
Agreement.
Under the terms of the LSA, Oxford Biomedica will receive
payments related to the development and manufacturing of lentiviral
vectors for use in clinical trials. Additionally, the agreement
allows for payments to the Group for the manufacture and supply of
lentiviral vectors for commercial use.
This partnership with a leader in the CAR-T field builds on the
longstanding partnerships with Novartis and Bristol Myers Squibb,
as well as the more recently announced partnership with Beam
Therapeutics.
John Dawson, Chief Executive Officer of Oxford Biomedica, said:
"Arcellx is one of the leading next-generation CAR-T developers
deploying a wide range of innovative technologies to bring
innovative CAR-T products into development. We are proud to be
working with a leader in the field of CAR-T that shares our vision
of delivering cell and gene therapies to save lives. This is yet
another valuable opportunity for our LentiVector(R) platform to
support innovative product development of CAR-T products further
highlighting Oxford Biomedica's position as a partner of
choice."
Rami Elghandour, Chairman and CEO of Arcellx said : "We look
forward to leveraging Oxford Biomedica's renowned LentiVector (R)
platform technology, and their industry-leading development and GMP
manufacturing expertise in the clinical and commercial development
of our CAR-T programmes."
-Ends-
Enquiries:
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, Head of Investor Relations
Consilium Strategic Communications: T: +44 (0)20 3709 5700
Mary-Jane Elliott / Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R)), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, CNS disorders and liver diseases. The Group has also
entered into a number of partnerships, including with Novartis,
Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics,
Santen, Beam Therapeutics and Boehringer Ingelheim, through which
it has long-term economic interests in other potential gene and
cell therapy products. Additionally, the Group has signed a 3-year
master supply and development agreement with AstraZeneca for
large-scale manufacturing of the adenoviral based COVID-19 vaccine
candidate, AZD1222. Oxford Biomedica is based across several
locations in Oxfordshire, UK and employs more than 740 people.
Further information is available at www.oxb.com
About Arcellx, Inc.
Arcellx is a clinical-stage biopharmaceutical company developing
adaptive and controllable cell therapies for the treatment of
patients with cancer and autoimmune diseases. The Arcellx vision is
to utilize our novel proprietary platform to bring superior cell
therapies to more patients through the care of academic and
community practices worldwide. More information can be found at
www.arcellx.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRBLLLFFLLFFBD
(END) Dow Jones Newswires
December 13, 2021 02:00 ET (07:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024